Private equity bidder under pressure to raise Clinigen offer

Bid for pharmaceutical company Clinigen

Elliot Gulliver-Needham
clock • 1 min read
Private equity bidder under pressure to raise Clinigen offer
Image:

Private equity bidder under pressure to raise Clinigen offer

Pressure has mounted on private equity firm Triton Investment Management to raise its offer on its £1.2bn bid for pharmaceutical company Clinigen.

Triton's 833p-per-share offer was made last month after recommendation from Clinigen's board, giving a 41% premium on Clinigen's ex-dividend share price before the offer period began. However, investors in the company, such as hedge fund Elliott Management, are arguing that the company's current share price of 916p shows that the company has been undervalued. Other investors which are thought to be arguing that the company is undervalued includes Sparta Capital, another activist fund, and Carlson Capital, which holds a position in Clinigen through derivatives. Amundi reframes busin...

To continue reading this article...

Join Investment Week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

Trustpilot